The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., & Riccardi, C. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90198-o · Cited by 4,579
Yuan, J. (1993) · Cell · doi:10.1016/0092-8674(93)90485-9 · Cited by 2,483
Human ICE/CED-3 Protease Nomenclature
Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., & Yuan, J. (1996) · Cell · doi:10.1016/s0092-8674(00)81334-3 · Cited by 2,372
INTRACELLULAR CALCIUM HOMEOSTASIS
Carafoli, E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.002143 · Cited by 2,190
Mechanisms and Functions of Cell Death
Ellis, R. E., Yuan, J., & Horvitz, H. R. (1991) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.07.110191.003311 · Cited by 2,057
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
Ju, S.-T., Panka, D. J., Cui, H., Ettinger, R., EI-Khatib, M., Sherr, D. H., Stanger, B. Z., & Marshak-Rothstein, A. (1995) · Nature · doi:10.1038/373444a0 · Cited by 1,499
Cited by
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Mounier, N. (2003) · Blood · doi:10.1182/blood-2002-11-3442 · Cited by 513
Rituximab: A Review of its Use in Non-Hodgkin??s Lymphoma and Chronic Lymphocytic Leukaemia
Plosker, G. L., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363080-00005 · Cited by 471
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T.-D. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 438
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Rituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial
Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R., & Specks, U. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1144oc · Cited by 399
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Rituximab: Mechanism of action and resistance
Maloney, D. G., Smith, B., & Rose, A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30156 · Cited by 375
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Cooper, N., Stasi, R., Cunningham‐Rundles, S., Feuerstein, M. A., Leonard, J. P., Amadori, S., & Bussel, J. B. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04889.x · Cited by 336
Jazirehi, A. R., & Bonavida, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208349 · Cited by 275
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
Malphettes, L., Freyvert, Y., Chang, J., Liu, P., Chan, E., Miller, J. C., Zhou, Z., Nguyen, T., Tsai, C., Snowden, A. W., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22751 · Cited by 164
Metadata
- Authors
- Shan, D., Ledbetter, J. A., & Press, O. W.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2000-02-23
- Volume
- 48
- Issue
- 12
- Pages
- 673-683
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2079756029
- Cited by
- 385
- References
- 47
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.